Curaleaf International, a division of Curaleaf Holdings, Inc. (TSX: CURA), has announced the launch of its medical cannabis products in Australia, a market projected to exceed $1 billion in annual sales by next year. This move is part of Curaleaf’s strategy to expand its operations in key international markets.
The initial release includes four cannabis flower strains, which will be distributed in collaboration with Canngea, a licensed Australian manufacturer and wholesaler experienced in the medical cannabis sector. This partnership allows Curaleaf to leverage Canngea’s expertise to ensure high-quality product delivery to Australian patients and healthcare providers.
Juan Martinez, Head of Curaleaf International, emphasized the importance of this launch in enhancing access to evidence-based cannabis medicines in Australia. The company aims to support local patients and healthcare professionals by providing consistent and reliable products backed by a robust supply chain.
Additionally, Curaleaf plans to introduce a wider range of products in the coming months, including precision-dosed inhalation formats and popular strains already prescribed in markets like the UK and Germany. This gradual expansion will help Curaleaf solidify its position in the Australian market and cater to the growing demand for medical cannabis.
Boris Jordan, Chairman and CEO of Curaleaf, described the Australian market as dynamic and rapidly developing, making it an attractive focus for Curaleaf’s global strategy. He noted that the company’s proven product portfolio and history of innovation will play a crucial role in establishing its presence in this new market.
Curaleaf International emphasizes its commitment to research and product excellence, supported by a strong presence across various stages of the cannabis supply chain. The company operates cultivation and processing facilities in Europe and Canada, ensuring that its products meet high safety and quality standards.
With this entry into Australia, Curaleaf aims to improve patient access to medical cannabis while continuing to expand its global footprint in the cannabis industry.
English 
Spanish 
German 
Czech